CMG Pharmaceutical Co. Ltd Asset Resilience Ratio

Latest as of December 2025: 6.66%

CMG Pharmaceutical Co. Ltd asset resilience ratio. CMG Pharmaceutical Co. Ltd (058820) has an Asset Resilience Ratio of 6.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CMG Pharmaceutical Co. Ltd (058820) liquidity interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩20.38 Billion
≈ $13.81 Million USD Cash + Short-term Investments

Total Assets

₩305.96 Billion
≈ $207.35 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of CMG Pharmaceutical Co. Ltd (2011–2025)

Asset resilience ratio of CMG Pharmaceutical Co. Ltd from 2011 to 2025. This chart shows how CMG Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. Read debt load of CMG Pharmaceutical Co. Ltd for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down CMG Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CMG Pharmaceutical Co. Ltd (058820) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩20.38 Billion 6.66%
Total Liquid Assets ₩20.38 Billion 6.66%

Asset Resilience Insights

  • Limited Liquidity: CMG Pharmaceutical Co. Ltd maintains only 6.66% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

CMG Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio

Compare CMG Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
Drug Manufacturers - Specialty & Generic 26.45%
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
Drug Manufacturers - Specialty & Generic 11.84%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Bide Pharmatech Co. Ltd. A
SHG:688073
Drug Manufacturers - Specialty & Generic 9.46%
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
Drug Manufacturers - Specialty & Generic 20.61%
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
Drug Manufacturers - Specialty & Generic 30.38%
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
Drug Manufacturers - Specialty & Generic 0.42%

CMG Pharmaceutical Co. Ltd Asset Resilience Ratio by Year (2011–2025)

CMG Pharmaceutical Co. Ltd asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for CMG Pharmaceutical Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 6.66% ₩20.38 Billion
≈ $13.81 Million
₩305.96 Billion
≈ $207.35 Million
-17.79pp
2024-12-31 24.46% ₩74.21 Billion
≈ $50.29 Million
₩303.44 Billion
≈ $205.63 Million
-3.46pp
2023-12-31 27.92% ₩67.58 Billion
≈ $45.80 Million
₩242.10 Billion
≈ $164.07 Million
-6.48pp
2022-12-31 34.40% ₩73.36 Billion
≈ $49.71 Million
₩213.26 Billion
≈ $144.52 Million
-10.96pp
2021-12-31 45.36% ₩90.34 Billion
≈ $61.22 Million
₩199.17 Billion
≈ $134.98 Million
-10.84pp
2020-12-31 56.19% ₩109.78 Billion
≈ $74.39 Million
₩195.36 Billion
≈ $132.39 Million
-6.01pp
2019-12-31 62.20% ₩119.57 Billion
≈ $81.03 Million
₩192.24 Billion
≈ $130.28 Million
+14.58pp
2018-12-31 47.62% ₩54.46 Billion
≈ $36.91 Million
₩114.38 Billion
≈ $77.51 Million
-4.22pp
2017-12-31 51.84% ₩56.80 Billion
≈ $38.49 Million
₩109.57 Billion
≈ $74.25 Million
-1.47pp
2016-12-31 53.31% ₩59.16 Billion
≈ $40.09 Million
₩110.98 Billion
≈ $75.21 Million
+44.46pp
2015-12-31 8.84% ₩5.00 Billion
≈ $3.39 Million
₩56.53 Billion
≈ $38.31 Million
+8.37pp
2014-12-31 0.48% ₩278.19 Million
≈ $188.53K
₩58.07 Billion
≈ $39.35 Million
-0.02pp
2013-12-31 0.50% ₩278.19 Million
≈ $188.53K
₩55.91 Billion
≈ $37.89 Million
-52.64pp
2012-12-31 53.14% ₩30.35 Billion
≈ $20.57 Million
₩57.11 Billion
≈ $38.70 Million
+49.22pp
2011-12-31 3.92% ₩1.07 Billion
≈ $726.07K
₩27.31 Billion
≈ $18.50 Million
--
pp = percentage points

About CMG Pharmaceutical Co. Ltd

KQ:058820 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$410.78 Million
₩606.15 Billion KRW
Market Cap Rank
#12907 Global
#366 in Korea
Share Price
₩4100.00
Change (1 day)
-1.68%
52-Week Range
₩536.00 - ₩4980.00
All Time High
₩8318.64
About

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more